BioCentury
ARTICLE | Clinical News

VX15/2503: Completed Phase II enrollment

September 19, 2016 7:00 AM UTC

Vaccinex completed enrollment of 89 patients with late prodromal and early manifest HD in the double-blind, placebo-controlled, U.S. Phase II SIGNAL trial evaluating 20 mg/kg IV VX15/2503 once monthly...